ChromaDex goes retail; loses (first round!) in court case with Elysium

ChromaDex announced at its recent shareholders meeting that they are in the process of marketing NR/Niagen on their own and are cutting off sales of NR (Nicotinamide Riboside) to vendors like Elysium as well as the 40 or so others as they are

“clearing the playing field for us to set the stage for us to make an investment in our own consumer product brand is a priority for us. The short answer is that we are clearing the playing field right now, and we expect it to be substantially cleared as this year progresses, and we expect a lot of it to be cleared by the end of the year…

….Most of them will eventually run out of inventory, but there is also the possibility that we may be able to clear it by potentially just taking some of that inventory on our own and removing it so that we can clear a path in a more efficient way. and we’re evaluating several different ways. I don’t foresee that it will go out for a long period of time that you’ll see a lot of inventory out there.”

ChromaDex added that they are “open to [selling NR to some vendors] but that’s all that we can say right now.”

To which I say “highly unlikely.” Why would ChromaDex spend millions of dollars transitioning to becoming a retailer of NR and still keep selling NR to a few large vendors?

Elysium has a large stock of NR from its unusually large purchase from ChromaDex last June, a month after its 120 person trial of NR at 250 mg and 500 mg started. To keep selling BASIS (NR with pterostilbine), Elysium could buy up other vendor’s stock that are willing to sell at a small marked up price. Then they could announced a new product that does not rely on NR or ptersotilbine later this year or early next year.

Also, ChromaDex has lost its [corrected: first round of the] court case against Elysium but Elysium’s complaints will still be heard. From The Right of Assembly that has been reporting on this case:

“The federal district court dismissed both of ChromaDex’s tort claims — fraudulent deceit and trade secrets — although ChromaDex is entitled to amend its complaint and assert with more specificity why the thing that Elysium allegedly stole was a trade secret.

The federal district court refused to dismiss Elysium’s fraud and patent misuse claims, but did dismiss Elysium’s unfair trade practices claim.”

This entry was posted in health, Health Pills and tagged , , , . Bookmark the permalink.

3 Responses to ChromaDex goes retail; loses (first round!) in court case with Elysium

  1. dave says:

    They did not lose the case. The Judge just made some preliminary rulings. Some hurt Chromadex, some hurt Elysium. The trial is just getting going with the first hearing tomorrow. Stay tuned its sure to be interesting.


  2. dave says:

    Doctors at Scripps Research used Niagen to boost Nad+ in cancer cells which stopped them from metastasizing. What is that worth to society? Google it.


  3. toddkreider says:

    Thanks a lot Dave. I’ve been waiting for news.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s